Full Press Release Details
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune
Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that
harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present
at the BIO CEO & Investor Conference being held February 14 - 17 at the Marriott Marquis in New York City.
BIO CEO & Investor Conference
Presentation Date: Tuesday, February 15, 2022
Presentation Time: 9:15 AM Eastern Time
Please contact your representative at BIO to schedule a virtual one-on-one
meeting with INmune Bio during the respective conference.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology
to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in
clinical trial to determine if it can treat cancer (INB03 ), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment
resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK
cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that
any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in
this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595, and INKmune are
still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they
will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially
from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce
more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described
in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report
on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes
no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of
David Moss, CFO (858) 964-3720